Biotech News

New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care

ImmunityBio (IBRX)ImmunityBioCompany update

In national survey of military service members and veterans with non-muscle invasive bladder cancer (NMIBC) (“respondents” throughout) conducted by The Harris Poll, 53% were diagnosed by age 50, and 28% were diagnosed by age 40 Among respondents who had not undergone a full removal of their bladder

Related news

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

Stock data

Close
6.57 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States